Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Nurix Therapeutics ( (NRIX) ).
Nurix Therapeutics unveiled promising data from its Phase 1a/1b trial of NX-5948 at the ASH Annual Meeting, showcasing a strong objective response rate of 75.5%, increasing to 84.2% with extended treatment. This BTK degrader showed a favorable safety profile and efficacy in patients with challenging genetic mutations, including those resistant to prior therapies. The trial continues to enroll participants, with pivotal trials set for 2025, marking a significant stride in tackling relapsed or refractory CLL/SLL.
See more insights into NRIX stock on TipRanks’ Stock Analysis page.
